SCHEMBL19781584

SCHEMBL19781584

CC(C)Oc1ccc(-c2ccc3cnc(-c4ccc(OC(C)C)cc4)n3c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
RAB9A P51151 2/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SCN5A Q14524 1/20 0.44
CYP1A2 P05177 1/20 0.41
FDPS P14324 2/20 0.40
MAPT P10636 2/20 0.39
MAP4K4 O95819 1/20 0.39
TP53 P04637 1/20 0.39
GSK3B P49841 3/20 0.39
CLK1 P49759 1/20 0.38
PTPN5 P54829 1/20 0.38
WDR5 P61964 1/20 0.37
CHEK1 O14757 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19781274 0.88 SCN5A (0.44) KDM4EALDH1A1MEN1KMT2ARAB9A
SCHEMBL19781273 0.84 SCN5A (0.43) KDM4EALDH1A1MEN1KMT2ARAB9A
SCHEMBL24460399 0.77 CLK1 (0.47) SCN5ACYP1A2FDPSMAPTMAP4K4
SCHEMBL19781140 0.75 SCN5A (0.50) KDM4EMEN1KMT2ASCN5ACYP1A2
SCHEMBL19781539 0.73 CLK1 (0.47) SCN5ACYP1A2CLK1WDR5
SCHEMBL19781261 0.72 CLK1 (0.47) SCN5ACYP1A2FDPSMAPTMAP4K4
SCHEMBL24460319 0.72 CLK1 (0.47) SCN5ACYP1A2FDPSMAPTMAP4K4
SCHEMBL19781550 0.72 FDPS (0.40) CYP1A2FDPSMAPTMAP4K4TP53
SCHEMBL19781270 0.72 CHEK1 (0.48) CYP1A2FDPSMAPTMAP4K4TP53
SCHEMBL26459346 0.71 RAB9A (0.57) KDM4EALDH1A1MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2022-09-08 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
WO-2018013430-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION C9, C1S, ZC3HAV1 KDM4E 966/4885ALDH1A1 1131/4885MEN1 4109/4885
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S KDM4E 838/4885ALDH1A1 1146/4885MEN1 3948/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S KDM4E 838/4885ALDH1A1 1146/4885MEN1 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.